Brain reserve moderates AD pathology associations with cognitive function in cognitively unimpaired adults

This study utilized a cross-sectional design to analyze baseline data collected from a multisite randomized clinical trial involving 621 participants. The cohort consisted of cognitively unimpaired, physically inactive, community-dwelling adults recruited from 3 US universities. Of the total sample, 355 participants had plasma p-tau-217 and PET for beta-amyloid data available for analysis. The primary exposure was AD pathology, quantified using plasma p-tau-217 and PET imaging for beta-amyloid. The primary outcomes measured were cognitive functions including episodic memory, processing speed, working memory, and executive function/attentional control. Secondary outcomes included brain-predicted age difference (brain-PAD), volumetric AD signature, years of education, and socioeconomic status (SES).

The analysis revealed that brain-PAD significantly moderated the association between AD pathology and cognitive function across all measured domains. Specifically, the negative association between AD pathology and cognitive performance was weakest in individuals exhibiting younger appearing brains. For episodic memory, the effect size (beta) was -0.09 with a 95% confidence interval of -0.16 to -0.02. Processing speed showed a beta of -0.08 with a confidence interval of -0.15 to -0.01. Working memory demonstrated a beta of -0.10 with a confidence interval of -0.18 to -0.03. Executive function/attentional control yielded a beta of -0.08 with a confidence interval of -0.15 to -0.01. In all instances, the direction of the association was negative, indicating that higher AD pathology correlated with lower cognitive function, but this correlation was attenuated by greater brain reserve.

Secondary analyses identified that latent SES score also moderated the relationship between p-tau217 and episodic memory. The effect size for this moderation was beta = 0.08, with a confidence interval of 0.01 to 0.16. The direction of this specific moderation effect was not explicitly reported in the source data. No adverse events, serious adverse events, discontinuations, or specific tolerability data were reported, as the study analyzed baseline data from a trial rather than an intervention arm. Consequently, safety and tolerability findings regarding the exposure or intervention are not applicable to this specific dataset.

These results align with the hypothesis that cognitive and brain reserve strategies can boost resilience against emerging AD pathology. However, the study design precludes direct comparison to prior landmark longitudinal studies regarding disease progression, as this analysis relied solely on cross-sectional baseline data. The cross-sectional nature of the design is a primary methodological limitation, preventing the establishment of causality. The observed associations are correlational; therefore, conclusions regarding the protective effect of brain reserve against pathology accumulation cannot be confirmed without longitudinal data.

Key limitations include the cross-sectional design and the lack of longitudinal follow-up to confirm conclusions. Potential biases related to the specific recruitment of physically inactive, community-dwelling adults may limit generalizability to more diverse populations. The study did not report funding sources or conflicts of interest. Given these constraints, the results support the hypothesis but require confirmation through longitudinal studies. Clinicians should interpret these findings as preliminary evidence suggesting that factors contributing to brain reserve may mitigate the cognitive impact of AD pathology, but practice decisions should await further validation.

Several questions remain unanswered. The long-term trajectory of individuals with high AD pathology but high brain reserve remains unknown. It is unclear whether interventions to increase brain reserve can effectively delay cognitive decline in the presence of pathology. The specific mechanisms by which brain-PAD moderates the pathology-cognition link require further investigation. Until longitudinal data are available, the clinical utility of targeting brain reserve to counteract AD pathology in cognitively unimpaired adults remains theoretical.